Topics:
Gastrointestinal Cancers • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University • Cholangiocarcinoma • NCI-CCC GI Tumor Board Question
Would you offer adjuvant capecitabine to a patient with resected intrahepatic cholangiocarcinoma after being treated with neoadjuvant GAP chemotherapy?
4 months of Neoadjuvant GAP resulted in conversion from unresectable to resectable.
Answer from: Medical Oncologist at Academic Institution
This is a good question without a clear right answer. In the randomized phase 3 BILCAP trial (Primrose et al., PMID 30922733), the per protocol analysis showed that adjuvant capecitabine improved overall survival compared to observation alone. However, this study excluded patients who had previous c...
Sign in or Register to read more